Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2026
|
| Online Access: | https://doi.org/10.5281/zenodo.18932204 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- <p>Cancer immunotherapy involves the use of therapeutic modalities that determine a<br>manipulation of the immune system by using immune agents such as cytokines, vaccines, cell<br>therapies and humoral, transfection agents. Immunotherapy of cancer has to stimulate the<br>host’s anti-tumour response by increasing the effector cell number and the production of<br>soluble mediators and decrease the host’s suppressor mechanisms by inducing tumour killing<br>environment and by modulating immune checkpoints. Immunotherapy seems to work better<br>in more immunogenic tumours. Compared with previous standards of care (including<br>chemotherapy, radiotherapy, and surgery), cancer immunotherapy has brought significant<br>improvements for patients in terms of survival and quality of life. Immunotherapy has now<br>firmly established itself as a novel pillar of cancer care. In this review we will see the<br>evolution of immunotherapy</p>